Search filters
Filters
Clear All

Phase

  • 3
  • 3
  • 7
  • 3
  • 17
  • 8
  • 17
  • 17

Found 17 Cardiomyopathy trials

A listing of Cardiomyopathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

99 years or below
All genders
Phase 3
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM. Approximately 220 participants will be enrolled. This includes ~80 participants (~40 per treatment group) who consent to participate in a …
Learn More

Study to Evaluate Safety and Efficacy of Ck3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

18 years - 99 years
All genders
Phase 3
The purpose of this study is to compare the effects of CK-3773274, and placebo, on the exercise and health status of patients with oHCM. The safety and tolerability of CK-3773274 will also be studied.
Learn More

A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

99 years or below
All genders
Phase 2
Please see section 1 of the full protocol
Learn More
Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

99 years or below
All genders
Phase 3
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …
Learn More
INFINITY-Prospective Cohort Study of Mechanistic Associations between Intra-Myocardial Fat Deposition and Ventricular Tachycardia in Ischemic Cardiomyopathy

INFINITY-Prospective Cohort Study of Mechanistic Associations between Intra-Myocardial Fat Deposition and Ventricular Tachycardia in Ischemic Cardiomyopathy

18 years - 99 years
All genders
This study will focus on fat buildup inside the heart muscle, a newly recognized factor that makes patients vulnerable to such fast heart rates, or ventricular tachycardia, after a heart attack. This work may identify more successful strategies for curing dangerously fast heart rates. Adult subjects with prior history of …
Learn More
Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Studying symptomatic Transthyretin Amyloid Cardiomyopathy for those who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

18 years - 99 years
All genders
Phase 3
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
Learn More

A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

99 years or below
All genders
This is a multicenter study to evaluate the long-term safety and tolerability of mavacamten in participants with nHCM who completed MAVERICK-HCM through Week 24 and enroll into this study within 3 months. All participants will receive active study drug as described below, but their status (active or placebo) in the …
Learn More
11 - 17 of 17